{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:52:03Z","timestamp":1792803123101,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jns.2012.08.005","type":"journal-article","created":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T16:07:36Z","timestamp":1346256456000},"page":"1-8","source":"Crossref","is-referenced-by-count":151,"title":["The kynurenine pathway in neurodegenerative diseases: Mechanistic and therapeutic considerations"],"prefix":"10.1016","volume":"323","author":[{"given":"Lin","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Tai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2012.08.005_bb0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2174\/187152707783399229","article-title":"Kynurenine pathway and disease: an overview","volume":"6","author":"P\u00e9rez-De La Cruz","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.jns.2012.08.005_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/IJTR.S2318","article-title":"Effects of kynurenine pathway metabolites on intracellular NAD+ synthesis and cell death in human primary astrocytes and neurons","volume":"2","author":"Braidy","year":"2009","journal-title":"Int J Tryptophan Res"},{"key":"10.1016\/j.jns.2012.08.005_bb0015","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.bbapap.2011.07.023","article-title":"Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors","volume":"1814","author":"Meininger","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jns.2012.08.005_bb0020","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-009-0263-4","article-title":"Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies","volume":"116","author":"Zadari","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2012.03.026","article-title":"Kynurenic acid and 3-hydroxykynurenine production from d-kynurenine in mice","volume":"1455","author":"Wang","year":"2012","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2012.08.005_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-9255-8-25","article-title":"Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts","volume":"8","author":"Asp","year":"2011","journal-title":"J Inflamm"},{"key":"10.1016\/j.jns.2012.08.005_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2009.02.326","article-title":"The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection","volume":"283","author":"Vamos","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0040","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ntt.2011.07.002","article-title":"On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress","volume":"33","author":"Lugo-Huitron","year":"2011","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.jns.2012.08.005_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jns.2007.01.033","article-title":"Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders","volume":"257","author":"Sas","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0050","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.ajpath.2011.05.048","article-title":"The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1","volume":"179","author":"Krause","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jns.2012.08.005_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10571-006-9124-y","article-title":"Kynurenines impair energy metabolism in rat cerebral cortex","volume":"27","author":"Schuck","year":"2007","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.jns.2012.08.005_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00702-010-0475-7","article-title":"Interferon-gamma-inducible kynurenines\/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders","volume":"118","author":"Oxenkrug","year":"2011","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2011.05.031","article-title":"Treating the periphery to ameliorate neurodegenerative diseases","volume":"145","author":"Reinhart","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jns.2012.08.005_bb0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1124\/mol.111.074765","article-title":"Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type-4 metabotropic glutamate receptors","volume":"81","author":"Fazio","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jns.2012.08.005_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2009.05356.x","article-title":"Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism","volume":"1199","author":"Oxenkrug","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0080","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clinbiochem.2004.02.007","article-title":"Increasing production of homocysteine and neopterin and degradation of tryptophan with older age","volume":"37","author":"Frick","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jns.2012.08.005_bb0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/10253890701685908","article-title":"Changes in brain tryptophan metabolism elicited by aging, social environment, and psychological stress in mice","volume":"11","author":"Miura","year":"2008","journal-title":"Stress"},{"key":"10.1016\/j.jns.2012.08.005_bb0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00702-011-0665-y","article-title":"Kynurenines and headache","volume":"119","author":"P\u00e1rdutz","year":"2012","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00702-011-0668-8","article-title":"New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid\/3-hydroxykynurenine ratio","volume":"119","author":"Kocki","year":"2012","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-6606-2-8","article-title":"Tryptophan 2, 3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice","volume":"2","author":"Kanai","year":"2009","journal-title":"Mol Brain"},{"key":"10.1016\/j.jns.2012.08.005_bb0105","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1111\/j.1742-4658.2011.08366.x","article-title":"Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats","volume":"278","author":"Braidy","year":"2011","journal-title":"FEBS J"},{"key":"10.1016\/j.jns.2012.08.005_bb0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1196\/annals.1403.003","article-title":"Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging","volume":"1122","author":"Oxenkrug","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000086295","article-title":"Age-related increase of kynurenic acid in human cerebrospinal fluid \u2014 IgG and \u00df2-microglobulin changes","volume":"14","author":"Kepplinger","year":"2005","journal-title":"Neurosignals"},{"key":"10.1016\/j.jns.2012.08.005_bb0120","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/jpet.110.177386","article-title":"Age dependency of inhibition of 7 nicotinic receptors and tonically active N-methyl-d-aspartate receptors by endogenously produced kynurenic acid in the brain","volume":"337","author":"Alkondon","year":"2011","journal-title":"J Parmacol Exp Ther"},{"key":"10.1016\/j.jns.2012.08.005_bb0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-2011-110131","article-title":"Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy","volume":"24","author":"Plangar","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jns.2012.08.005_bb0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF03033908","article-title":"The involvement of astrocytes and kynurenine pathway in Alzheimer's disease","volume":"12","author":"Ting","year":"2007","journal-title":"Neurotox Res"},{"key":"10.1016\/j.jns.2012.08.005_bb0135","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1471-4159.2009.06175.x","article-title":"Proinflammatory cytokine interferon-\u0263 increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid \u03b2 peptide 1-42:implications for the pathogenesis of Alzheimer's disease","volume":"110","author":"Yamada","year":"2009","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.jns.2012.08.005_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1179\/174329210X12650506623645","article-title":"Indoleamine 2, 3-dioxygenase and 3-OH-kynurenine modifications are found in the neuropathology of Alzheimer Disease","volume":"15","author":"Bonda","year":"2010","journal-title":"Redox Rep"},{"key":"10.1016\/j.jns.2012.08.005_bb0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","article-title":"Kynurenine and its metabolites in Alzheimer's disease patients","volume":"55","author":"Gulaj","year":"2010","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0150","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/j.1582-4934.2010.01123.x","article-title":"Kynurenines, neurodegeneration and Alzheimer's disease","volume":"14","author":"Kincses","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jns.2012.08.005_bb0155","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1471-4159.2009.05868.x","article-title":"Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid","volume":"108","author":"Coggan","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2012.08.005_bb0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuint.2006.08.012","article-title":"Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease","volume":"50","author":"Hartai","year":"2007","journal-title":"Neurochem Int"},{"key":"10.1016\/j.jns.2012.08.005_bb0165","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.sbi.2008.09.009","article-title":"Curiosity to kill the KAT (kynurenine aminotransferase):structural insights into brain kynurenic acid synthesis","volume":"18","author":"Rossi","year":"2008","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.jns.2012.08.005_bb0170","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","article-title":"Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration","volume":"145","author":"Zwilling","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jns.2012.08.005_bb0175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JAD-2010-100684","article-title":"Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro","volume":"22","author":"Yu","year":"2010","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.jns.2012.08.005_bb0180","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbr.2010.02.041","article-title":"Protective effect of systemic l-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25\u201335) in rat hippocampus","volume":"210","author":"Carrillo-Mora","year":"2010","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jns.2012.08.005_bb0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.mehy.2011.05.022","article-title":"Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer's disease","volume":"77","author":"Gong","year":"2011","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jns.2012.08.005_bb0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5414\/CPP48633","article-title":"Medical treatment of Parkinson's disease: today and the future","volume":"48","author":"G\u00e1rdi\u00e1n","year":"2010","journal-title":"J Clin Pharmacol Ther"},{"key":"10.1016\/j.jns.2012.08.005_bb0195","first-page":"220","article-title":"Glutamate, excitotoxicity and programmed cell death in Parkinson disease","volume":"3","author":"Caudle","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jns.2012.08.005_bb0200","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jns.2011.07.021","article-title":"Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach","volume":"310","author":"Szabo","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0205","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1582-4934.2010.01237.x","article-title":"Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines","volume":"15","author":"Zadori","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jns.2012.08.005_bb0210","first-page":"716859","article-title":"The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease","author":"Zinger","year":"2011","journal-title":"Park Dis"},{"key":"10.1016\/j.jns.2012.08.005_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2005.07.006","article-title":"Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease","volume":"239","author":"Hartai","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00401-006-0086-4","article-title":"Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra","volume":"112","author":"Knyihar-Csillik","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jns.2012.08.005_bb0225","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ejcb.2008.03.003","article-title":"Kynurenic acid attenuates MPP+-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway","volume":"87","author":"Lee do","year":"2008","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.jns.2012.08.005_bb0230","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","article-title":"Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington's disease mice","volume":"23","author":"Guidetti","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jns.2012.08.005_bb0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-011-0697-3","article-title":"Kynurenines in Parkinson's disease: therapeutic perspectives","volume":"119","author":"Z\u00e1dori","year":"2012","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-3-211-45295-0_45","article-title":"Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies","volume":"70","author":"N\u00e9meth","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.jns.2012.08.005_bb0245","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00702-009-0253-6","article-title":"Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease","volume":"116","author":"Vamos","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0250","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ntt.2010.10.002","article-title":"Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy","volume":"33","author":"Silva-Adava","year":"2011","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.jns.2012.08.005_bb0255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00702-009-0346-2","article-title":"A novel kynurenic acid analogue: a comparison with kynurenic acid: an electrophysiological study","volume":"117","author":"Marosi","year":"2010","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00228-009-0742-4","article-title":"Novel therapeutic strategies in Parkinson's disease","volume":"66","author":"Klivenyi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jns.2012.08.005_bb0265","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1471-4159.2009.05893.x","article-title":"On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo","volume":"109","author":"Amori","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2012.08.005_bb0270","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jns.2007.01.033","article-title":"Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders","volume":"257","author":"Sas","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0275","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","article-title":"The kynurenine pathway modulates neurodegeneration in a drosophila model of Huntington's disease","volume":"21","author":"Campesan","year":"2011","journal-title":"Curr Biol"},{"key":"10.1016\/j.jns.2012.08.005_bb0280","doi-asserted-by":"crossref","first-page":"513","DOI":"10.33549\/physiolres.931049","article-title":"Integrative hypothesis for Huntington's disease: a brief review of experimental evidence","volume":"56","author":"Perez-De La Cruz","year":"2007","journal-title":"Physiol Res"},{"key":"10.1016\/j.jns.2012.08.005_bb0285","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","article-title":"Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington's disease","volume":"113","author":"Santhyasaikumar","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2012.08.005_bb0290","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/187152710793237430","article-title":"Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease","volume":"9","author":"Thevandavakkam","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.jns.2012.08.005_bb0295","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pneurobio.2009.04.005","article-title":"Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease","volume":"90","author":"Schwarcz","year":"2010","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jns.2012.08.005_bb0300","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","article-title":"Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease","volume":"17","author":"Guidetti","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jns.2012.08.005_bb0305","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pneurobio.2006.11.003","article-title":"N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease","volume":"81","author":"Fan","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jns.2012.08.005_bb0310","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","article-title":"A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease","volume":"37","author":"Giorgini","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jns.2012.08.005_bb0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","article-title":"Endogenous kynurenate controls the vulnerability of strial neurons to quinolinate: implications for Huntington's disease","volume":"197","author":"Sapko","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jns.2012.08.005_bb0320","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neuroscience.2007.05.033","article-title":"Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-d-aspartate neurotoxicity","volume":"148","author":"Poeggeler","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.jns.2012.08.005_bb0325","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00702-010-0573-6","article-title":"Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease","volume":"118","author":"Zadori","year":"2011","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.08.005_bb0330","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1074\/jbc.M708192200","article-title":"Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment","volume":"283","author":"Glorgini","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jns.2012.08.005_bb0335","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/187152409787601941","article-title":"Recent advances in the treatment of amyotrophic lateral sclerosis: emphasis on kynurenine pathway inhibitors","volume":"9","author":"Chen","year":"2009","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"10.1016\/j.jns.2012.08.005_bb0340","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000089622","article-title":"Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis","volume":"2","author":"Gillemin","year":"2005","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.jns.2012.08.005_bb0345","doi-asserted-by":"crossref","first-page":"24078","DOI":"10.1074\/jbc.M302051200","article-title":"Bicarbonate-dependent peroxidase activity of human Cu, Zn-superoxide dismutase induces covalent aggregation of protein: intermediacy of tryptophan-derived oxidation products","volume":"278","author":"Zhang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jns.2012.08.005_bb0350","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12640-009-9129-7","article-title":"The kynurenine pathway and inflammation in amyotrophic lateral sclerosis","volume":"18","author":"Chen","year":"2010","journal-title":"Neurotox Res"},{"key":"10.1016\/j.jns.2012.08.005_bb0355","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1471-4159.2010.07159.x","article-title":"Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis","volume":"118","author":"Chen","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2012.08.005_bb0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000223353.34006.54","article-title":"Neuroprotective agents for clinical trials in ALS: a systematic assessment","volume":"67","author":"Trayno","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2012.08.005_bb0365","first-page":"899","article-title":"Research on an in vitro cell system for testing the neurotoxicity of kynurenine pathway metabolites","volume":"66","author":"Wszelaki","year":"2011","journal-title":"Pharmazie"},{"key":"10.1016\/j.jns.2012.08.005_bb0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00023210-200923020-00001","article-title":"Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders","volume":"23","author":"Erhardt","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2012.08.005_bb0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jns.2012.08.005_bb0380","doi-asserted-by":"crossref","first-page":"22021","DOI":"10.1074\/jbc.M603503200","article-title":"Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35","volume":"281","author":"Wang","year":"2006","journal-title":"J Biol Chem"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X12004340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X12004340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T19:59:09Z","timestamp":1714334349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X12004340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":76,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0022510X12004340"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2012.08.005","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}